Literature DB >> 9553763

Dipeptidyl-peptidase IV/CD26 on T cells: analysis of an alternative T-cell activation pathway.

A von Bonin1, J Hühn, B Fleischer.   

Abstract

CD26 is a proteolytic enzyme (dipeptidyl-peptidase IV) with a wide tissue distribution and a unique specificity that was already described 27 years ago. CD26 is expressed on a fraction of resting T cells at low density but is strongly upregulated following T-cell activation. Recent results indicate that CD26 is a multifunctional molecule that may have important functions on T cells and in the immune system. It is associated with molecules of immunological importance such as the protein tyrosine phosphatase CD45 and adenosine deaminase (ADA) on the cell surface. Synthetic inhibitors of the enzymatic activity of CD26 have been shown to suppress certain immune reactions in vitro and in vivo. An interesting feature of CD26 is its ability to transmit a transmembrane signal to trigger functional programs in T cells. This triggering requires crosslinking of CD26 on a cell membrane. The enzymatic activity of CD26 is not obligatory for the activation of T cells via CD26. Since CD26 is a type II membrane protein with only six intracellular amino acids, it must deliver its signal via a signal-transducing molecule. Signaling is dependent on the expression of the T-cell receptor (TCR) complex with a special need for a functional zeta-chain. In this context the zeta-chain of the TCR complex is required for CD26-mediated signaling but, in contrast to other co-stimulatory molecules such as the CD2 molecule, is not sufficient for triggering the T cell.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9553763     DOI: 10.1111/j.1600-065x.1998.tb01570.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  23 in total

1.  Enzymatic properties of dipeptidyl aminopeptidase IV produced by the periodontal pathogen Porphyromonas gingivalis and its participation in virulence.

Authors:  Y Kumagai; K Konishi; T Gomi; H Yagishita; A Yajima; M Yoshikawa
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  CD26 inhibition enhances allogeneic donor-cell homing and engraftment after in utero hematopoietic-cell transplantation.

Authors:  William H Peranteau; Masayuki Endo; Obinna O Adibe; Aziz Merchant; Philip W Zoltick; Alan W Flake
Journal:  Blood       Date:  2006-09-05       Impact factor: 22.113

3.  Identity of activation molecule 3 on superantigen-stimulated bovine cells is CD26.

Authors:  S U Lee; W Ferens; W C Davis; M J Hamilton; Y H Park; L K Fox; J Naessens; G A Bohach
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

4.  G1/S cell cycle arrest provoked in human T cells by antibody to CD26.

Authors:  Kei Ohnuma; Tomonori Ishii; Satoshi Iwata; Osamu Hosono; Hiroshi Kawasaki; Masahiko Uchiyama; Hirotoshi Tanaka; Tadanori Yamochi; Nam H Dang; Chikao Morimoto
Journal:  Immunology       Date:  2002-11       Impact factor: 7.397

Review 5.  Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review.

Authors:  Bart Stragier; Dimitri De Bundel; Sophie Sarre; Ilse Smolders; Georges Vauquelin; Alain Dupont; Yvette Michotte; Patrick Vanderheyden
Journal:  Heart Fail Rev       Date:  2007-11-08       Impact factor: 4.214

Review 6.  T-cell activation via CD26 and caveolin-1 in rheumatoid synovium.

Authors:  Kei Ohnuma; Hiroshi Inoue; Masahiko Uchiyama; Tadanori Yamochi; Osamu Hosono; Nam H Dang; Chikao Morimoto
Journal:  Mod Rheumatol       Date:  2006       Impact factor: 3.023

7.  CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1.

Authors:  Kei Ohnuma; Tadanori Yamochi; Masahiko Uchiyama; Kunika Nishibashi; Noritada Yoshikawa; Noriaki Shimizu; Satoshi Iwata; Hirotoshi Tanaka; Nam H Dang; Chikao Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-07       Impact factor: 11.205

8.  Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver.

Authors:  Sumaiya Chowdhury; Yiqian Chen; Tsun-Wen Yao; Katerina Ajami; Xin M Wang; Yury Popov; Detlef Schuppan; Patrick Bertolino; Geoffrey W McCaughan; Denise Mt Yu; Mark D Gorrell
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.742

9.  The in vivo expression of dipeptidyl peptidases 8 and 9.

Authors:  Denise M T Yu; Katerina Ajami; Margaret G Gall; Joohong Park; C Soon Lee; Kathryn A Evans; Eileen A McLaughlin; Melissa R Pitman; Catherine A Abbott; Geoffrey W McCaughan; Mark D Gorrell
Journal:  J Histochem Cytochem       Date:  2009-07-06       Impact factor: 2.479

10.  Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.

Authors:  Kalpit A Vora; Gene Porter; Roche Peng; Yan Cui; Kellyann Pryor; George Eiermann; Dennis M Zaller
Journal:  BMC Immunol       Date:  2009-04-09       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.